JP2005507932A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005507932A5 JP2005507932A5 JP2003539676A JP2003539676A JP2005507932A5 JP 2005507932 A5 JP2005507932 A5 JP 2005507932A5 JP 2003539676 A JP2003539676 A JP 2003539676A JP 2003539676 A JP2003539676 A JP 2003539676A JP 2005507932 A5 JP2005507932 A5 JP 2005507932A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- represents hydrogen
- pharmaceutically acceptable
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 65
- 239000001257 hydrogen Substances 0.000 claims 65
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 64
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 63
- 150000002148 esters Chemical class 0.000 claims 39
- 150000003839 salts Chemical class 0.000 claims 39
- 150000001875 compounds Chemical class 0.000 claims 32
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 23
- 125000001424 substituent group Chemical group 0.000 claims 21
- 239000003937 drug carrier Substances 0.000 claims 20
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical group 0.000 claims 16
- 229940079593 drug Drugs 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 12
- 125000004104 aryloxy group Chemical group 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 229910052717 sulfur Inorganic materials 0.000 claims 11
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 239000003472 antidiabetic agent Substances 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 9
- 125000004432 carbon atom Chemical group C* 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 8
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 6
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 5
- ZILVNHNSYBNLSZ-UHFFFAOYSA-N 2-(diaminomethylideneamino)guanidine Chemical compound NC(N)=NNC(N)=N ZILVNHNSYBNLSZ-UHFFFAOYSA-N 0.000 claims 5
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 claims 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 5
- 206010020772 Hypertension Diseases 0.000 claims 5
- 102000004877 Insulin Human genes 0.000 claims 5
- 108090001061 Insulin Proteins 0.000 claims 5
- 229940122199 Insulin secretagogue Drugs 0.000 claims 5
- 229940100389 Sulfonylurea Drugs 0.000 claims 5
- 238000010521 absorption reaction Methods 0.000 claims 5
- 239000000048 adrenergic agonist Substances 0.000 claims 5
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 5
- 239000003613 bile acid Substances 0.000 claims 5
- 239000011230 binding agent Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 229940125753 fibrate Drugs 0.000 claims 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 5
- 229940125396 insulin Drugs 0.000 claims 5
- 230000008991 intestinal motility Effects 0.000 claims 5
- 230000004130 lipolysis Effects 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 230000036186 satiety Effects 0.000 claims 5
- 235000019627 satiety Nutrition 0.000 claims 5
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 5
- 230000035924 thermogenesis Effects 0.000 claims 5
- 239000003316 glycosidase inhibitor Substances 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- -1 benzyloxycarbonylamino Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 0 C*C(CCC*1)C1C1CC1 Chemical compound C*C(CCC*1)C1C1CC1 0.000 description 4
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32923601P | 2001-10-12 | 2001-10-12 | |
| PCT/US2002/032895 WO2003037332A1 (en) | 2001-10-12 | 2002-10-15 | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005507932A JP2005507932A (ja) | 2005-03-24 |
| JP2005507932A5 true JP2005507932A5 (enExample) | 2006-01-05 |
Family
ID=23284480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003539676A Withdrawn JP2005507932A (ja) | 2001-10-12 | 2002-10-15 | 肥満の処置のためのフェニル置換５−員窒素含有複素環 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050014805A1 (enExample) |
| EP (1) | EP1435951B1 (enExample) |
| JP (1) | JP2005507932A (enExample) |
| CA (1) | CA2463441A1 (enExample) |
| DE (1) | DE60208815T2 (enExample) |
| ES (1) | ES2256560T3 (enExample) |
| MX (1) | MXPA04002931A (enExample) |
| WO (1) | WO2003037332A1 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003007887A2 (en) | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| ATE486842T1 (de) | 2002-03-12 | 2010-11-15 | Merck Sharp & Dohme | Substituierte amide |
| WO2004058727A1 (en) * | 2002-12-20 | 2004-07-15 | Bayer Pharmaceuticals Corporation | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| JP2006518738A (ja) * | 2003-02-12 | 2006-08-17 | トランス テック ファーマ，インコーポレイテッド | 治療薬としての置換アゾール誘導体 |
| EP1622876A1 (en) * | 2003-05-07 | 2006-02-08 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
| JP2007512227A (ja) | 2003-08-06 | 2007-05-17 | セノミックス、インコーポレイテッド | Ｔ１ｒヘテロオリゴマー味覚受容体、この受容体を発現する細胞株、および味覚化合物 |
| CN100572375C (zh) | 2004-01-28 | 2009-12-23 | 霍夫曼-拉罗奇有限公司 | 螺－苯并间二氧杂环戊烯及其作为cb1拮抗剂的应用 |
| US20050187277A1 (en) * | 2004-02-12 | 2005-08-25 | Mjalli Adnan M. | Substituted azole derivatives, compositions, and methods of use |
| WO2005090340A1 (ja) * | 2004-03-22 | 2005-09-29 | Banyu Pharmaceutical Co., Ltd. | ピペリジン－１－カルボキサミド誘導体 |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| MXPA06012130A (es) * | 2004-04-20 | 2007-01-31 | Transtech Pharma Inc | Derivados de tiazol y pirimidina substituidos como moduladores del receptor de melanocortina. |
| BRPI0517653A (pt) | 2004-11-09 | 2008-10-14 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos |
| MX2007009388A (es) | 2005-02-04 | 2007-09-25 | Senomyx Inc | Compuestos que comprenden porciones heteroarilo unidas y su uso como modificadores del sabor unami, saborizantes y mejoradores del sabor para composiciones comestibles. |
| EP1848428A4 (en) | 2005-02-18 | 2012-04-18 | Neurogen Corp | THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGS |
| CA2607953A1 (en) | 2005-05-09 | 2006-11-16 | Tap Pharmaceutical Products, Inc. | Methods for treating nephrolithiasis |
| AR055329A1 (es) | 2005-06-15 | 2007-08-15 | Senomyx Inc | Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor |
| JP5242393B2 (ja) * | 2005-08-03 | 2013-07-24 | タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド | 高血圧症の治療方法 |
| WO2007052843A1 (ja) * | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
| AU2007211319B9 (en) | 2006-01-30 | 2012-05-31 | Vtv Therapeutics Llc | Substituted imidazole derivatives and their use as PTPase inhibitors |
| EP3235811B1 (en) | 2006-04-21 | 2018-07-25 | Senomyx, Inc. | Process of preparing oxalamides |
| MX2009013293A (es) | 2007-06-04 | 2010-02-15 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| CA2691662A1 (en) * | 2007-07-02 | 2009-01-08 | F. Hoffmann-La Roche Ag | Imidazole derivatives as ccr2 receptor antagonists |
| CN101808995A (zh) | 2007-07-27 | 2010-08-18 | 百时美施贵宝公司 | 新颖的葡糖激酶激活剂及其使用方法 |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
| DK2303021T3 (en) | 2008-06-16 | 2019-04-08 | Univ Tennessee Res Found | RELATIONSHIPS FOR TREATING CANCER |
| CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP2320738A4 (en) * | 2008-08-29 | 2011-08-24 | Transtech Pharma Inc | SUBSTITUTED AMINOTHIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
| AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| KR101939704B1 (ko) | 2010-03-01 | 2019-01-17 | 지티엑스, 인코포레이티드 | 암 치료용 화합물 |
| MX2013001313A (es) | 2010-08-05 | 2013-06-13 | Amgen Inc | Compuestos de bencimidazol y azabencimidazol que inhiben la cinasa del linfoma anaplasico. |
| ES2532210T3 (es) | 2010-09-10 | 2015-03-25 | Takeda Pharmaceuticals U.S.A., Inc. | Métodos para el tratamiento concomitante de teofilina y febuxostat |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| MX348131B (es) | 2011-02-25 | 2017-05-26 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos. |
| WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| EP3404032B1 (en) * | 2013-03-13 | 2025-07-02 | F. Hoffmann-La Roche AG | Process for making benzoxazepin compounds |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
| JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
| EA201592263A1 (ru) | 2013-06-05 | 2016-05-31 | Синерджи Фармасьютикалз, Инк. | Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP3212642B1 (en) * | 2014-10-30 | 2019-10-30 | Janssen Pharmaceutica NV | Amide substituted thiazoles as modulators of rorgammat |
| BR112018016360A2 (pt) * | 2016-02-11 | 2018-12-18 | Bayer Cropscience Aktiengesellschaft | 2-(het)arilimidazolilcarboxiamidas substituídas como pesticidas |
| TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑 |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| CA3103929A1 (en) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Phenyl substituted pyrazoles as modulators of roryt |
| ES2925473T3 (es) | 2018-06-18 | 2022-10-18 | Janssen Pharmaceutica Nv | Pirazoles de piridinilo como moduladores de RORyt |
| EP3806958B1 (en) | 2018-06-18 | 2022-09-07 | Janssen Pharmaceutica NV | 6-aminopyridin-3-yl pyrazoles as modulators of roryt |
| CN112334450A (zh) | 2018-06-18 | 2021-02-05 | 詹森药业有限公司 | 作为RORγt的调节剂的苯基和吡啶基取代的咪唑 |
| CN111333636B (zh) * | 2020-04-10 | 2021-12-17 | 福建太平洋制药有限公司 | 噻唑酰胺类衍生物及其在抗肿瘤药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US69849A (en) * | 1867-10-15 | sheppaed | ||
| WO1998022108A1 (en) * | 1996-11-20 | 1998-05-28 | Merck & Co., Inc. | Triaryl substituted imidazoles and methods of use |
| CA2275610A1 (en) * | 1996-12-16 | 1998-06-25 | Ontogen Corporation | Modulators of proteins with phosphotyrosine recognition units |
| SK100099A3 (en) * | 1997-01-28 | 2000-05-16 | Merck & Co Inc | Thiazole benzenesulfonamides as 'beta'3 agonists for the treatment of diabetes and obesity |
| FR2763337B1 (fr) * | 1997-05-13 | 1999-08-20 | Sanofi Sa | Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant |
| AU778393B2 (en) * | 1999-05-12 | 2004-12-02 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
| PE20011010A1 (es) * | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
-
2002
- 2002-10-15 US US10/490,826 patent/US20050014805A1/en not_active Abandoned
- 2002-10-15 JP JP2003539676A patent/JP2005507932A/ja not_active Withdrawn
- 2002-10-15 CA CA002463441A patent/CA2463441A1/en not_active Abandoned
- 2002-10-15 DE DE60208815T patent/DE60208815T2/de not_active Expired - Fee Related
- 2002-10-15 EP EP02782159A patent/EP1435951B1/en not_active Expired - Lifetime
- 2002-10-15 MX MXPA04002931A patent/MXPA04002931A/es active IP Right Grant
- 2002-10-15 WO PCT/US2002/032895 patent/WO2003037332A1/en not_active Ceased
- 2002-10-15 ES ES02782159T patent/ES2256560T3/es not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004537541A5 (enExample) | ||
| RU2011152891A (ru) | Диарилгидантоины | |
| JP2004536115A5 (enExample) | ||
| CA2488535A1 (en) | Glucocorticoid receptor ligands for the treatment of metabolic disorders | |
| PE20000726A1 (es) | Derivados terapeuticos de biarilo | |
| PE20081316A1 (es) | COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA | |
| JP2008504265A5 (enExample) | ||
| JP2008044952A5 (enExample) | ||
| JP2011500658A5 (enExample) | ||
| JP2002508362A5 (ja) | １−置換−１−アミノメチル−シクロアルカン誘導体（＝ガバペンチン類縁体） | |
| RU2005119646A (ru) | Конденсированные бициклические азотсодержащие гетероциклы | |
| JP2007505164A5 (enExample) | ||
| RU2005138134A (ru) | Получение и применение арилалкильных производных кислот для лечения ожирения | |
| PE20020354A1 (es) | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) | |
| RU2485107C2 (ru) | Антималярийные соединения с гибкими боковыми цепями | |
| JP2011527334A5 (enExample) | ||
| JP2009521441A5 (enExample) | ||
| CA2614529A1 (en) | Pyridazinone derivatives as thyroid hormone receptor agonists | |
| ES2314418T3 (es) | Derivados de amidas del acido 4-bromo-5-(2-clorobenzoilamino)-1h-pirazol-3-carboxicilico y compuestos relacionados como antagonistas del receptor b1 de bradiquinina para el tratamiento de enfermedades inflamatorias. | |
| JP2010502730A5 (enExample) | ||
| JP2009530398A5 (enExample) | ||
| JP2005504100A5 (enExample) | ||
| JP2011513410A5 (enExample) | ||
| AR055015A1 (es) | Derivados fusionados de pirazol composicion farmaceutica y uso del compuesto para fabricar medicamentos. | |
| JP5727636B2 (ja) | 選択的アンドロゲン受容体調節因子の固体形態 |